Bio-Techne Corporation reported its financial results for the quarter and nine months ended March 31, 2026, revealing a decline in net sales and a significant increase in profitability compared to the same period last year. For the quarter, the company generated net sales of $311.4 million, a decrease of 1.5% from $316.2 million in the prior year. However, net earnings rose to $51.0 million, or $0.33 per share, compared to $22.6 million, or $0.14 per share, in the same quarter of 2025. For the nine-month period, net sales totaled $893.8 million, down from $902.7 million, while net earnings increased to $127.2 million from $91.1 million.
The financial performance reflects a strategic reduction in operating expenses, which fell to $132.8 million for the quarter, down from $175.8 million a year earlier. This reduction was primarily driven by a decrease in selling, general, and administrative expenses, which dropped to $109.3 million from $151.3 million. The company also reported an operating income of $75.5 million for the quarter, significantly higher than the $38.7 million recorded in the same quarter last year. The improved profitability was attributed to cost management initiatives and operational efficiencies.
In terms of operational developments, Bio-Techne has continued to focus on its core product lines, with consumables revenue remaining stable at $257.3 million for the quarter, compared to $257.8 million in the prior year. However, instrument sales saw a slight increase to $27.7 million from $26.1 million, while service revenues decreased to $21.4 million from $27.2 million. The company also reported a geographic breakdown of sales, with the United States contributing $167.5 million, down from $181.9 million, while EMEA sales increased to $73.4 million from $66.5 million.
Looking ahead, Bio-Techne's management expressed optimism about future growth, citing ongoing investments in research and development and potential market expansion opportunities. The company is also focused on enhancing its product offerings and exploring strategic acquisitions to bolster its market position. As of March 31, 2026, Bio-Techne had a total of 156.5 million shares outstanding and reported a cash and cash equivalents balance of $209.8 million, up from $162.2 million at the end of the previous fiscal year. The company remains committed to maintaining a strong financial position while navigating the challenges of the current market environment.
About BIO-TECHNE Corp
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and diagnostic products for research, diagnostics, and bioprocessing markets worldwide. Its two main segments—Protein Sciences and Diagnostics & Spatial Biology—offer biological reagents, protein analysis tools, molecular diagnostics, and spatial biology solutions. Serving academic, pharmaceutical, biotech, and clinical customers, Bio-Techne leverages innovation, quality manufacturing, and a broad global distribution network to support scientific discovery and disease diagnosis.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.